Introduction
The alterations of bone metabolism in patients with chronic liver disease (CLD) represent an important complication that has been in the researchers attention in the last years. This pathology associated with osteoporosis or osteopenia, and rarely with osteomalacia may conduct to morbidity (bone pain, skeletal deformities, immobility and fragility fractures).1 All the alterations of bone metabolism that appear in the evolution of CLD are defined as hepatic osteodystrophy (HO).2 HO is a common complication of CLD and it involves impairment of bone mineral density (BMD) so that an assessment should be made in patients with CLD in order to preserve the quality of life and also the long term prognosis.3 There are many factors that
The alterations of bone metabolism in patients with chronic liver disease (CLD) represent an important complication that has been in the researchers attention in the last years. This pathology associated with osteoporosis or osteopenia, and rarely with osteomalacia may conduct to morbidity (bone pain, skeletal deformities, immobility and fragility fractures).1 All the alterations of bone metabolism that appear in the evolution of CLD are defined as hepatic osteodystrophy (HO).2 HO is a common complication of CLD and it involves impairment of bone mineral density (BMD) so that an assessment should be made in patients with CLD in order to preserve the quality of life and also the long term prognosis.3 There are many factors that